Longitudinal changes in maternal soluble endoglin and angiopoietin-2 in women at risk for pre-eclampsia

Ultrasound in Obstetrics and Gynecology

Volumn 44, Issue 4, 2014, Pages 402-410

  Khalil, A ^a   Maiz, N ^b   Garcia Mandujano, R ^c   Elkhouli, M ^c   Nicolaides, K H ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b HOSPITAL DE CRUCES   (Spain)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Angiopoietin 2; Endoglin; Gestational hypertension; Pre eclampsia; Pregnancy screening

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADULT; BLOOD; BLOOD PRESSURE; FEMALE; HUMAN; LONGITUDINAL STUDY; MATERNAL HYPERTENSION; METABOLISM; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PROSPECTIVE STUDY;

ADULT; ANGIOPOIETIN-2; ANTIGENS, CD; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LONGITUDINAL STUDIES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE;

EID: 84908155913     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.13439     Document Type: Article

References (54)

1. Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D, Harper A, Hulbert D, Lucas S, McClure J, Millward-Sadler H, Neilson J, Nelson-Piercy C, Norman J, OHerlihy C, Oates M, Shakespeare J, de Swiet M, Williamson C, Beale V, KnightM, Lennox C, Miller A, Parmar D, Rogers J, Springett A. Saving Mothers Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 (Suppl 1):1-203.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
3. World Health Organization. Make Every Mother and Child Count. World Health Report, 2005. World Health Organization: Geneva, Switzerland, 2005.
4. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, DAmore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. NatMed 2006; 12: 642-649.
5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
6. Stepan H, Kramer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007; 92: 2831-2834.
7. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in pre-eclampsia. J Clin Endocrinol Metab 2007; 92: 2672-2679.
8. Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008; 29: 555-563.
9. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, DAnna R. Endoglin, PlGF and sflt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 837-842.
10. Kim YN, Lee DS, Jeong DH, Sung MS, Kim KT. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn 2009; 29: 464-470.
11. Reddy A, Suri S, Sargent IL, Redman CW, Muttukrishna S. Maternal circulating levels of activin a, inhibin a, sflt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia. PLoS One 2009; 4: e4453.
12. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137-142.
13. Robinson CJ, Johnson DD. Soluble endoglin as a secondtrimester marker for preeclampsia. Am J Obstet Gynecol 2007; 197: 174.e1-5.
14. Lim JH, Kim SY, Park SY, Lee MH, Yang JH, Kim MY, Chung JH, Lee SW, Ryu HM. Soluble endoglin and transforming growth factor-1 in women who subsequently developed preeclampsia. Prenat Diagn 2009; 29: 471-476.
15. Baumann MU, Bersinger NA, Mohaupt MG, Raio L, Gerber S, Surbek DV. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia. Am J Obstet Gynecol 2008; 199: 266.e1-6.
16. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH. Maternal plasma soluble endoglin at 11-13 weeks gestation in pre-eclampsia. Ultrasound Obstet Gynecol 2010; 35: 680-687.
17. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, Cherney DZ, Hladunewich MA. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010; 122: 1846-1853.
18. NooriM, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
19. Savvidou MD, Noori M, Anderson JM, Hingorani AD,NicolaidesKH. Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008; 32: 871-876.
20. Lai J, Syngelaki A, Poon LC, Nucci M, Nicolaides KH.Maternal serum soluble endoglin at 30-33 weeks in the prediction of preeclampsia. Fetal Diagn Ther 2013; 33: 149-155.
21. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. JMatern Fetal NeonatalMed 2008; 21: 9-23.
22. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-287.
23. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, Suthanthiran M, August P. Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 2012; 59: 740-746.
24. Myatt L, Clifton RG, Roberts JM, Spong CY, Wapner RJ, Thorp JMJr, Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Sciscione A, Tolosa JE, Saade G, Sorokin Y, Anderson GD; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? BJOG 2013; 120: 1183-1191.
25. Smith GC, Wear H. The perinatal implications of angiogenic factors. Curr Opin Obstet Gynecol 2009; 21: 111-116.
26. Hirokoshi K, Maeshima Y, Kobayashi K, Matsuura E, Sugiyama H,Yamasaki Y,Masuyama H,Hiramatsu Y, Makino H. Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens 2005; 18: 1181-1188.
27. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005; 94: 1071-1076.
28. Han SY, Jun JK, Lee CH, Park JS, Syn HC. Angiopoietin-2: a promising indicator for the occurrence of severe preeclampsia. Hypertens Pregnancy 2012; 31: 189-199.
29. Bolin M, Wiberg-Itzel E, Wikström AK, Goop M, Larsson A, Olovsson M, Akerud H. Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens 2009; 22: 891-895.
30. Leinonen E, Wathen KA, Alfthan H, Ylikorkala O, Andersson S, Stenman UH, Vuorela P. Maternal serum angiopoietin-1 and -2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab 2010; 95: 126-133.
31. Zhang EG, Smith SK, Baker PN, Charnock-Jones DS. The regulation and localisation of angiopoietin-1, -2 and their receptor Tie2 in normal and pathologic human placentae. Mol Med 2001; 7: 624-635.
32. Akolekar R, Casagrandi D, Skyfta E, Ahmed AA, Nicolaides KH. Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn 2009; 29: 847-851.
33. Farina A, Zucchini C, De Sanctis P, Morano D, Sekizawa A, Purwosunu Y, Okai T, Rizzo N. Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre-eclampsia later in pregnancy: implications for screening. Prenat Diagn 2011; 31: 181-185.
34. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A, Jaffe RB. Human placental vascular development: vasculogenic and angiogenic (branching and non-branching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 2002; 87: 4213-4224.
35. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31: 66-74.
36. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
37. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, LetarteM. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992; 267: 19 027-19 030.
38. St-Jacques S, Forte M, Lye SJ, Letarte M. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 1994; 51: 405-413.
39. Raab U, Velasco B, Lastres P, Letamendia A, Cales C, Langa C, Tapia E, Lopez-Bote JP, Paez E, Bernabéu C. Expression of normal and truncated forms of human endoglin. Biochem J 1999; 339: 579-588.
40. Raab U, Lastres P, Arévalo MA, Lopez-Novoa JM, Cabañas C, de la Rosa EJ, Bernabeu C. Endoglin is expressed in the chicken vasculature and is involved in angiogenesis. FEBS Lett 1999; 459: 249-254.
41. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003; 17: 984-992.
42. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005; 96: 684-692.
43. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260-266.
44. Cudmore M,Ahmad S, Al-Ani B, Fujisawa T,Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A,Hewett PW,Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
45. Saad AF,Kechichian T, Yin H, Sbrana E, Longo M,Wen M, Tamayo E, Hankins GD, Saade GR, Costantine MM. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 2014; 21: 138-145.
46. Ramma W, Ahmed A. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol 2014; 101-102: 153-160.
47. Babischkin JS, Suresch DL, Pepe GJ, Albrecht ED. Differential expression of placental villous angiopoietin-1 and -2 during early, mid and late baboon pregnancy. Placenta 2007; 28: 212-218.
48. Charnock-Jones DS, Kaufmann P, Mayhew TM. Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 2004; 25: 103-113.
49. Seval Y, Sati L, Celik-Ozenci C, Taskin O, Demir R. The distribution of angiopoietin-1, angiopoietin-2 and their receptors tie-1 and tie-2 in the very early human placenta. Placenta 2008; 29: 809-815.
50. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
51. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99: 11 205-11 210.
52. Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, Sato TN, Yancopoulos GD. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-471.
53. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
54. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T, Sukhatme VP, Woolf AS, Karumanchi SA. Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J 2007; 21: 3171-3183.